6922 — Cryofocus Medtech (Shanghai) Co Income Statement
0.000.00%
Last trade - 00:00- HK$1.47bn
- HK$1.44bn
- CNY53.53m
Annual income statement for Cryofocus Medtech (Shanghai) Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 9.05 | 22.4 | 27.1 | 41 | 53.5 |
| Cost of Revenue | |||||
| Gross Profit | 4.64 | 15.5 | 19.4 | 31.1 | 38.4 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 168 | 149 | 145 | 146 | 164 |
| Operating Profit | -159 | -126 | -118 | -105 | -110 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -159 | -126 | -118 | -106 | -111 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -159 | -126 | -118 | -106 | -111 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -137 | -102 | -112 | -97.5 | -104 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -137 | -102 | -112 | -97.5 | -104 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.573 | -0.374 | -0.582 | -0.408 | -0.411 |